Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib and Cetuximab With or Without Nivolumab in BRAFV600E Metastatic Colorectal Cancer
NCT05308446Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2022
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nivolumab in colorectal cancer (CRC), sponsored by National Cancer Institute. Started Jul 2022; status: active, not recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05308446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05308446.